Key result
Valsartan combined with hydrochlorothiazide significantly increased the total effective rate to 95.45% compared to 79.63% with valsartan alone in patients with hypertensive heart disease.
Why the study?
The study was conducted to investigate the effectiveness of combining valsartan and hydrochlorothiazide in managing hypertensive heart disease.
Does valsartan combined with hydrochlorothiazide improve cardiac function and blood pressure in patients with hypertensive heart disease compared to valsartan alone?
Cohort (n=120)
No
Does valsartan combined with hydrochlorothiazide improve cardiac function and blood pressure in patients with hypertensive heart disease compared to valsartan alone?
Absolute Event Rate: 95.45% vs 79.63%
p-value: p=0.007
The combination of valsartan and hydrochlorothiazide is more effective than valsartan monotherapy in improving blood pressure and cardiac function in patients with hypertensive heart disease.
May support combination use for BP and LV parameters in hypertensive heart disease; hypothesis-generating and leaves open need for randomized confirmation.
Purpose: To investigate the effectiveness of the combination of valsartan and hydrochlorothiazide in managing hypertensive heart disease.Methods: From August 2020 to October 2022, the case data of 120 patients in Lu’an Hospital of Anhui Medical University, Lu’an, China were analyzed retrospectively. Based on the different treatment options, 54 patients with hypertensive heart disease who received valsartan alone (80 mg, once daily) for 3 months were placed in control group (CG), while 66 patients who received valsartan combined with Systolic blood pressure (SBP), therapeutic effect, diastolic blood pressure (DBP), and incidence of adverse effects were also recorded for CG and SG.Results: In the SG, there were significant reductions in SBP, DBP, LVMI and LVPWT compared to CG, while EF showed significant increase after treatment (p < 0.05). In both groups, SBP, DBP, LVMI and LVPWT decreased significantly after treatment compared to pre-treatment values, but EF however showed a significant increase (p < 0.05). In the SG, there was a significant increase (p < 0.05) in the total effective rate compared to CG and there was also a significant reduction (p < 0.05) in the total incidence of adverse effects compared to CG.Conclusion: Valsartan combined with hydrochlorothiazide is more effective in treating patients with hypertensive heart disease than valsartan monotherapy alone. However, the combination treatment should be subjected to further clinical trials prior to its introduction into clinical practice.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) conducted a cohort in Hypertensive heart disease (n=120). Valsartan and hydrochlorothiazide vs. Valsartan alone (80-160 mg/day) was evaluated on Total effective rate (p=0.007). Valsartan combined with hydrochlorothiazide significantly increased the total effective rate to 95.45% compared to 79.63% with valsartan alone in patients with hypertensive heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: